Timing of GLP-1 Receptor Agonist Initiation for Treatment of Type 2 Diabetes in the UK

por Boye, Kristina S., Stein, Dara, Matza, Louis S., Jordan, Jessica, Yu, Ren, Norrbacka, Kirsi, Hassan, Syed Wasi, García-Pérez, Luis-Emilio
Publicado 2019

Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn’s disease patients: a German retrospectiv...

por Helwig, Ulf, Mross, Michael, Schubert, Stefan, Hartmann, Heinz, Brandes, Alina, Stein, Dara, Kempf, Christian, Knop, Jana, Campbell-Hill, Sarah, Ehehalt, Robert
Publicado 2020

Vedolizumab and Anti-Tumour Necrosis Factor α Real-World Outcomes in Biologic-Naïve Inflammatory Bowel Disease Patients: Results from the EVOLVE Study

por Bressler, Brian, Yarur, Andres, Silverberg, Mark S, Bassel, Marielle, Bellaguarda, Emanuelle, Fourment, Chris, Gatopoulou, Anthie, Karatzas, Pantelis, Kopylov, Uri, Michalopoulos, George, Michopoulos, Spyridon, Navaneethan, Udayakumar, Rubin, David T, Siffledeen, Jesse, Singh, Andrew, Soufleris, Konstantinos, Stein, Dara, Demuth, Dirk, Mantzaris, Gerassimos J
Publicado 2021